1955P SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2579